oru.sePublications
Change search
Refine search result
1 - 16 of 16
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Rows per page
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sort
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
Select
The maximal number of hits you can export is 250. When you want to export more records please use the Create feeds function.
  • 1.
    Ekström, Mats
    et al.
    Örebro University, Department of Humanities.
    Johansson, Bengt
    Larsson, Larsåke
    Örebro University, Department of Humanities.
    Journalism and local politics: A study of scrutiny and accountability in Swedish journalism2006In: Journalism Studies, ISSN 1461-670X, E-ISSN 1469-9699, Vol. 7, no 2, p. 292-311Article in journal (Refereed)
    Abstract [en]

    Political accountability is defined as an important aspect of scrutiny. By analysing newspapers at three different points in time (1961, 1981 and 2001), this study suggests that the kind of scrutiny often mentioned in the literature, characterised by thorough investigations and disclosures of political wrongdoings, barely exists in the local press. By identifying other forms of scrutiny more closely related to ordinary news reporting, the study shows that one-third of the 1500 articles analysed display some degree of scrutiny. The local press plays an important role in communicating information and critique concerning the ways in which local authority service provision works and how political responsibilities are fulfilled. This study indicates that this role has been strengthened during the second half of the 20th century.

  • 2.
    Ekström, Mats
    et al.
    Örebro University, Department of Humanities.
    Johansson, Bengt
    Larsson, Larsåke
    Örebro University, Department of Humanities.
    Mot en mer oberoende kommunal journalistik?2006In: Nordicom Information, ISSN 0349-5949, Vol. 28, no 4, p. 37-53Article in journal (Other academic)
  • 3.
    Hjortshøj, Cristel Sørensen
    et al.
    Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
    Jensen, Annette Schophuus
    Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
    Sørensen, Keld
    Department of Internal Medicine, Aalborg University Hospital, Farsoe, Denmark.
    Nagy, Edit
    Department of Internal Medicine, Aalborg University Hospital, Farsoe, Denmark.
    Johansson, Bengt
    Örebro University Hospital. Örebro University, School of Medical Sciences. Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
    Kronvall, Thomas
    Department of Cardiology, Örebro University Hospital, Örebro, Sweden.
    Dellborg, Mikael
    Department of Cardiology, Sahlgrenska University Hospital, Göteborg, Sweden.
    Estensen, Mette-Elise
    Department of Cardiology, Rikshospitalet, Oslo, Norway.
    Holmstrøm, Henrik
    Department of Paediatric Cardiology, Rikshospitalet, Oslo, Norway.
    Turanlahti, Maila
    Department of Pediatric Cardiology, Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, Finland.
    Thilén, Ulf
    Department of Cardiology, Lund University Hospital, Lund, Sweden.
    Søndergaard, Lars
    Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
    Epidemiological changes in Eisenmenger syndrome in the Nordic region in 1977-20122017In: Heart, ISSN 1355-6037, E-ISSN 1468-201X, Vol. 103, no 17, p. 1353-1358Article in journal (Refereed)
    Abstract [en]

    OBJECTIVE: Improved diagnostic tools, timely closure of the shunt and a better understanding of the complexity of Eisenmenger syndrome (ES) have led to improved care and treatment in tertiary centres. These may have decreased the incidence of ES and improved survival of patients with ES, although evidence is still lacking. The aim of this study was to investigate temporal changes in incidence, prevalence and mortality in patients with ES for 35 years in the Nordic region.

    METHODS: This was a retrospective population-based study including 714 patients with ES. Survival analysis was performed based on all-cause mortality and accounting for immortal time bias.

    RESULTS: The incidence of ES decreased from 2.5/million inhabitants/year in 1977 to 0.2/million inhabitants/year in 2012. Correspondingly, prevalence decreased from 24.6 to 11.9/million inhabitants. The median survival was 38.4 years, with 20-year, 40-year and 60-year survival of 72.5%, 48.4%, and 21.3%, respectively. Complex lesions and Down syndrome were independently associated with worse survival (HR 2.2, p<0.001 and HR 1.8, p<0.001, respectively). Age at death increased from 27.7 years in the period from 1977 to 1992, to 46.3 years from July 2006 to 2012 (p<0.001).

    CONCLUSIONS: The incidence and prevalence of ES in the Nordic region have decreased markedly during the last decades. Furthermore, the median age at death increased throughout the study period, indicating prolonged life expectancy in the ES population. However, increasing age represents decreased incidence, rather than improved survival. Nonetheless, longevity with ES is still shorter than in the background population.

  • 4.
    Johansson, Bengt
    Örebro University, School of Health and Medical Sciences.
    Long-term outcome research on PDR brachytherapy with focus on breast, base of tongue and lip cancer2010Doctoral thesis, comprehensive summary (Other academic)
    Abstract [en]

    Brachytherapy (BT) with continuous low dose rate (LDR) has been used for 100 years and is considered as the radiotherapy method able to deliver a dose in the shortest time with high efficacy and low risk of side effects. The drawbacks are need for patient isolation and radiation exposure of the staff during the treatment.

    Brenner and Hall published the radiobiology concept for pulsed dose rate (PDR) in 1991.  Short (10-20 minutes), hourly pulses of high dose rate (HDR) given to the same dose, with same overall treatment time will virtually simulate continuous LDR. At the same time new afterloading machine technology became available, where a single millimetre sized radiation 192Iridium source sequentially moves through the applicator in small individually timed steps. The advantages are that the radiation dose can be optimized along the applicator and with no radiation exposure of the staff and no need for patient isolation more than during the pulse. This work deals with four different aspects of PDR BT

    An experimental comparison of measured absorbed doses outside a left sided breast target on a body equivalent Alderson phantom was made.  Five external beam radiotherapy (EBRT) whole breast treatments to 50 Gy versus five accelerated partial breast irradiations (APBI) by PDR BT to 50 Gy were studied. The absorbed doses were measured in 67 different positions inside the body phantom by thermoluminescence dosimeters. The result shows that dose points distant to the left breast will have 1-1.4 % of the prescribed dose with no difference between EBRT and PDR BT. Organs at risk in short distance (<5 cm) to the target (such as parts of the left lung, heart muscle and the right breast) will have significantly less dose by PDR BT. In conclusion PDR BT has dosimetric advantages close to the target compared to EBRT and cannot do more damage to remote organs.

    PDR APBI as the adjuvant RT treatment to breast conserving surgery after early breast cancer was studied. Between 1994-2004 we treated 50 women and 51 breasts. The median age of the population was 53 (40-72) years. The cases were radically resected, unifocal T1-2N0-1M0 tumours. PDR BT was given to a dose of 50 Gy for 5 days directed to the operated sector of the breast. The median treated volume was 160 cm3, constituting in median 31 % of the breast volume. The treatment is called accelerated because total treatment time is 5 days compared to 5 weeks for EBRT. After a median follow-up of 130 months (>10 years) we noted 5 (10 %) local recurrences in the treated breast. Four of these recurrences were outside the treated volume. Three women (6 %) developed cancers in the other breast. Early side effects were mild and less than with EBRT. As late side effects we found mild to moderate local fibroses in the treated volume. A cosmetic evaluation was done by both the patient and a nurse and was found to be lower than in other published data (56 % = good to excellent). The 10 years local failure rate is similar to the result from a large Swedish randomized study on whole breast radiotherapy to 50 Gy. The study indicates that PDR BT is highly effective.

    A combination of EBRT (40.8 Gy) and PDR boost (35 Gy) to T1-4N0-3M0, base of tongue (BOT) cancer, treated during 1994-2007 was analyzed. The study is the first with PDR and second largest with BT worldwide. A number of 83 patients with a median age of 60 (38-82) years were included. BT was given to a mean volume of 58 ccm 2 days after the neck dissection. Median follow-up was 54 months. At 5 years we found 89 % local tumour control, 95 % neck control, 80 % disease free survival and an overall survival of 65 %. Late side effects were 13 % minor transient soft tissue necrosis and 12 % long lasting or permanent soft tissue- or osteoradio-necrosis. The results are among the best published worldwide. An extensive quality of life analysis was done on 45 patients at last follow-up and showed limited, persistent xerostomia and dysphagia. The global quality of life was rated good in 75 % of the patients.

    The last study presented was PDR mono-brachytherapy (55-60 Gy) to cancer of the lip (T1-3N0M0). The study included 43 patients with a median age of 74 (37-92) years. The treatment time was 5.5-6 days and the mean treated volume was 15 ccm. The median follow-up time was 54 (1-158) months. Five year Kaplan-Meier data showed, local control 94 %, disease free survival 86 % and overall survival 59 %. An early side effect was a strong radiation mucositis and dermatitis, which healed in 1 month. Late side effects were uncommon and the cosmetic appearance and the lip function were found to be normal. Our data in total and per T-stage was compared to a European survey from 1993 on 2794 patients treated by LDR BT. The results are similar and are a strong indication of equal efficacy between PDR and LDR.

    List of papers
    1. Phantom study of radiation doses outside the target volume brachytherapy versus external radiotherapy of early breast cancer
    Open this publication in new window or tab >>Phantom study of radiation doses outside the target volume brachytherapy versus external radiotherapy of early breast cancer
    2003 (English)In: Radiotherapy and Oncology, ISSN 0167-8140, E-ISSN 1879-0887, Vol. 69, no 1, p. 107-112Article in journal (Refereed) Published
    Abstract [en]

    BACKGROUND AND PURPOSE: Brachytherapy is sometimes suggested as an adjuvant treatment after surgery of some tumours. When introducing this, it would be useful to have an estimate of the dose distribution to different body sites, both near and distant to target, comparing conventional external irradiation to brachytherapy. The aim of the present study was to determine radiation doses with both methods at different body sites, near and distant to target, in an experimental situation on an operated left sided breast cancer on a female Alderson phantom. METHODS: Five external beam treatments with isocentric tangential fields were given by a linear accelerator. A specified dose of 1.0 Gy was given to the whole left sided breast volume. Five interstitial brachytherapy treatments were given to the upper, lateral quadrant of the left breast by a two plane, 10 needles implant. A dose of 1.0 Gy specified according to the Paris system was administered by a pulsed dose rate afterloading machine. Absorbed dose in different fixed dose points were measured by thermoluminescence dosimeters. RESULTS: Both methods yielded an absorbed dose of the same size to the bone marrow and internal organs distant to target, 1.0-1.4% of the prescribed dose. There was a trend of lower doses to the lower half of the trunk and higher doses to the upper half of the trunk, respectively, by brachytherapy. A 90% reduction of absorbed dose with brachytherapy compared to external irradiation was found in the near-target region within 5 cm from target boundary where parts of the left lung and the heart are situated. If an adjuvant dose of 50 Gy is given with the external radiotherapy and brachytherapy, the absorbed dose in a part of the myocardium could be reduced from 31.8 to 2.1 Gy. CONCLUSIONS: Near target, brachytherapy yielded a considerably lower absorbed dose which is of special importance when considering radiation effects on the myocard and lungs. We could not demonstrate any difference of importance, in absorbed dose to dose points distant to target.

    Place, publisher, year, edition, pages
    Amsterdam: Elsevier, 2003
    Keywords
    Brachytherapy; PDR; External radiotherapy; Breast cancer; Radiation dose distribution; TL dosimetry
    National Category
    Cancer and Oncology
    Research subject
    Oncology
    Identifiers
    urn:nbn:se:oru:diva-10402 (URN)10.1016/S0167-8140(03)00241-X (DOI)14597363 (PubMedID)
    Available from: 2010-04-20 Created: 2010-04-20 Last updated: 2017-12-12Bibliographically approved
    2. Pulsed dose rate brachytherapy as the sole adjuvant radiotherapy after breast-conserving surgery of T1-T2 breast cancer: first long time results from a clinical study
    Open this publication in new window or tab >>Pulsed dose rate brachytherapy as the sole adjuvant radiotherapy after breast-conserving surgery of T1-T2 breast cancer: first long time results from a clinical study
    Show others...
    2009 (English)In: Radiotherapy and Oncology, ISSN 0167-8140, E-ISSN 1879-0887, Vol. 90, no 1, p. 30-35Article in journal (Refereed) Published
    Abstract [en]

    BACKGROUND AND PURPOSE: To evaluate the long time outcome with regard to local tumour control, cosmetic outcome and side effects of a short (5 days) accelerated interstitial brachytherapy treatment delivered to the surroundings of the operated sector. PATIENTS AND METHODS: Between 1993 and 2003 we treated 50 women with early T1 and T2 breast cancer. Radical sector resection was performed and followed later with an interstitial pulsed dose rate (PDR) brachytherapy of 50Gy in 5 days. The treatment was centred on the tumour with a margin of 30mm. One patient was treated bilaterally. The patients were followed for a median of 86 (32-126) months. RESULTS: Ipsilateral breast cancer recurrence was seen in 3 patients (6%). Two of them occurred outside the treated volume. The 5- and 7-year rates of actuarial local control were 96% and 96%, respectively, overall survival 88% and 85%, disease free survival 88% and 88%, respectively. A dosimetrical analysis showed that the partial breast irradiation covered a median of 31% of the total breast volume. Fat necrosis was seen in 12% and local (moderate-strong) fibrosis in 26% of the patients. Independent cosmetic scoring showed good or excellent result in 56% of the patients. CONCLUSIONS: Local outcome is favourable and very similar to other published studies of accelerated partial breast irradiation. Our long time cosmetic results are lower than other published results.

    Place, publisher, year, edition, pages
    Amsterdam: Elsevier, 2009
    Keywords
    Brachytherapy; Pulsed dose rate; Breast cancer; Accelerated partial breast irradiation; Cosmetics; Outcome; Radiotherapy
    National Category
    Cancer and Oncology
    Research subject
    Oncology
    Identifiers
    urn:nbn:se:oru:diva-10401 (URN)10.1016/j.radonc.2008.02.022 (DOI)000262958000004 ()18410975 (PubMedID)2-s2.0-58149235035 (Scopus ID)
    Available from: 2010-04-20 Created: 2010-04-20 Last updated: 2017-12-12Bibliographically approved
    3. Long term results from a uniform clinical series on pulsed dose rate brachytherapy as the boost to external beam irradiation in base of tongue cancer
    Open this publication in new window or tab >>Long term results from a uniform clinical series on pulsed dose rate brachytherapy as the boost to external beam irradiation in base of tongue cancer
    Show others...
    (English)Manuscript (preprint) (Other academic)
    Abstract [en]

    Background and purpose: To evaluate the long time outcome with regard to local tumour control, side effects and quality of life of a combined pulsed dose rate (PDR) boost and hyperfractionated accelerated external beam radiotherapy (EBRT) for primary base of tongue (BOT) cancers.

    Patients and methods: Between 1994 and 2007 we treated 83 patients, median age 60 (38-82) years, with primary T1-T4 BOT cancers. Seven patients (8 %) were T1-2N0 (AJCC stage I-II) and 76 (92 %) patients were T1-2N+ or T3-4N0-3 (AJCC stage III-IV). The mean estimated primary tumour volume was 15 (1-75) cm3.  EBRT was given with 1.7 Gy twice daily to 40,8 Gy to primary tumour and bilateral neck lymph nodes in 2.5 weeks. A PDR boost of 35 Gy and a neck dissection in clinical node positive cases was performed 2-3 weeks later. The patients were followed for a median of 54 (2-168) months.

    Results: The 2-, 5- and 10-years rates of actuarial local control were 91 %, 89 % and 85 %, overall survival 85 %, 65 % and 44 %, disease free survival 86 %, 80 % and 76 % respectively. The regional contral rate was 95 %. Six patients (7 %) developed distant metastases. Analysis of dosimetry showed a mean treated volume of 58 cm3.  In a review of late complications we found 11 (13 %) minor and 4 (5 %) major soft tissue necroses and 6 (7 %) osteoradionecroses. The patients median subjective SOMA/LENT scoring at last follow up was; grade 0 for pain and trismus, grade 1 for dysphagia and taste alteration and grade 2 for xerostomia. Global visual-analog-scale (VAS) scoring of quality of life was 8.

    Conclusions: Local and regional tumour control rate was excellent in this treatment protocol. The data support that PDR boost is at least as effective as published continuous low dose rate (CLDR) results.

    Keywords
    Brachytherapy; Pulsed dose rate; Base of Tongue cancer; Outcome; Radio-therapy
    National Category
    Cancer and Oncology
    Research subject
    Oncology
    Identifiers
    urn:nbn:se:oru:diva-10406 (URN)
    Available from: 2010-04-20 Created: 2010-04-20 Last updated: 2017-10-18Bibliographically approved
    4. Pulsed dose rate monobrachytherapy for cancer of the lip: first long time results from a clinical study
    Open this publication in new window or tab >>Pulsed dose rate monobrachytherapy for cancer of the lip: first long time results from a clinical study
    (English)Manuscript (preprint) (Other academic)
    Abstract [en]

    Background and purpose: To evaluate the long time outcome with regard to local tumour control and side effects of a pulsed dose rate (PDR) monobrachytherapy of primary or recurrent cancr of the lip.

    Patients and methods: Between 1995 and 2007 we treated 43 patients with primary or recurrent T1-T3 lip cancers. The clinical stage was T1N0 for 22 patients (51 %), T2N0 for 16 patients (37 %) and T3N0 for 5 patients (12 %). A median dose of 60 (55-66) Gy was given, depending on the tumour volume. The PDR treatment was given with 0.83 Gy/pulse every second hour for 5.5-6.5 days. The patients were followed for a median of 55 (1-158) months.

    Results: The 2-, 5- and 10-years rates of actuarial local control were 97.6 %, 94.5 % and 94.5 %, overall survival 88.0 %, 58.9 % and 39.1 %, disease free survival 92.7 %, 86.4 % and 86.4 % respectively. The regional control rate was 93 %. One patient (2 %) developed distant metastases. A dosimetrical analysis showed a mean treated volume of 14.9 (3.0-56.2) cm3.  In a review of late complications we found 1 (2 %) soft tissue necrosis and 1 (2 %) osteoradionecrosis. Long-term side effects were very mild and the cosmetic outcome excellent.

    Conclusions: Local outcome is excellent and very similar to other published studies of continuous low dose rate (cLDR) brachytherapy.

    Keywords
    Brachytherapy; Pulsed dose rate; Lip cancer; Outcome; Radiotherapy
    National Category
    Cancer and Oncology
    Research subject
    Oncology
    Identifiers
    urn:nbn:se:oru:diva-10417 (URN)
    Available from: 2010-04-20 Created: 2010-04-20 Last updated: 2017-10-18Bibliographically approved
  • 5.
    Johansson, Bengt
    et al.
    Örebro University, School of Health and Medical Sciences.
    Karlsson, Leif
    Örebro University, School of Health and Medical Sciences.
    Hardell, Lennart
    Örebro University, School of Health and Medical Sciences.
    Persliden, Jan
    Örebro University, School of Health and Medical Sciences.
    Pulsed dose rate monobrachytherapy for cancer of the lip: first long time results from a clinical studyManuscript (preprint) (Other academic)
    Abstract [en]

    Background and purpose: To evaluate the long time outcome with regard to local tumour control and side effects of a pulsed dose rate (PDR) monobrachytherapy of primary or recurrent cancr of the lip.

    Patients and methods: Between 1995 and 2007 we treated 43 patients with primary or recurrent T1-T3 lip cancers. The clinical stage was T1N0 for 22 patients (51 %), T2N0 for 16 patients (37 %) and T3N0 for 5 patients (12 %). A median dose of 60 (55-66) Gy was given, depending on the tumour volume. The PDR treatment was given with 0.83 Gy/pulse every second hour for 5.5-6.5 days. The patients were followed for a median of 55 (1-158) months.

    Results: The 2-, 5- and 10-years rates of actuarial local control were 97.6 %, 94.5 % and 94.5 %, overall survival 88.0 %, 58.9 % and 39.1 %, disease free survival 92.7 %, 86.4 % and 86.4 % respectively. The regional control rate was 93 %. One patient (2 %) developed distant metastases. A dosimetrical analysis showed a mean treated volume of 14.9 (3.0-56.2) cm3.  In a review of late complications we found 1 (2 %) soft tissue necrosis and 1 (2 %) osteoradionecrosis. Long-term side effects were very mild and the cosmetic outcome excellent.

    Conclusions: Local outcome is excellent and very similar to other published studies of continuous low dose rate (cLDR) brachytherapy.

  • 6.
    Johansson, Bengt
    et al.
    Örebro University, School of Health and Medical Sciences.
    Karlsson, Leif
    Örebro University, School of Health and Medical Sciences.
    Liljegren, Göran
    Örebro University, School of Health and Medical Sciences.
    Hardell, Lennart
    Persliden, Jan
    Örebro University, School of Health and Medical Sciences.
    Pulsed dose rate brachytherapy as the sole adjuvant radiotherapy after breast-conserving surgery of T1-T2 breast cancer: first long time results from a clinical study2009In: Radiotherapy and Oncology, ISSN 0167-8140, E-ISSN 1879-0887, Vol. 90, no 1, p. 30-35Article in journal (Refereed)
    Abstract [en]

    BACKGROUND AND PURPOSE: To evaluate the long time outcome with regard to local tumour control, cosmetic outcome and side effects of a short (5 days) accelerated interstitial brachytherapy treatment delivered to the surroundings of the operated sector. PATIENTS AND METHODS: Between 1993 and 2003 we treated 50 women with early T1 and T2 breast cancer. Radical sector resection was performed and followed later with an interstitial pulsed dose rate (PDR) brachytherapy of 50Gy in 5 days. The treatment was centred on the tumour with a margin of 30mm. One patient was treated bilaterally. The patients were followed for a median of 86 (32-126) months. RESULTS: Ipsilateral breast cancer recurrence was seen in 3 patients (6%). Two of them occurred outside the treated volume. The 5- and 7-year rates of actuarial local control were 96% and 96%, respectively, overall survival 88% and 85%, disease free survival 88% and 88%, respectively. A dosimetrical analysis showed that the partial breast irradiation covered a median of 31% of the total breast volume. Fat necrosis was seen in 12% and local (moderate-strong) fibrosis in 26% of the patients. Independent cosmetic scoring showed good or excellent result in 56% of the patients. CONCLUSIONS: Local outcome is favourable and very similar to other published studies of accelerated partial breast irradiation. Our long time cosmetic results are lower than other published results.

  • 7.
    Johansson, Bengt
    et al.
    Örebro University, School of Health and Medical Sciences.
    Karlsson, Leif
    Örebro University, School of Health and Medical Sciences.
    Reizenstein, Johan
    Örebro University, School of Health and Medical Sciences.
    von Beckerath, Mathias
    Örebro University, School of Health and Medical Sciences.
    Hardell, Lennart
    Örebro University, School of Health and Medical Sciences.
    Persliden, Jan
    Örebro University, School of Health and Medical Sciences.
    Long term results from a uniform clinical series on pulsed dose rate brachytherapy as the boost to external beam irradiation in base of tongue cancerManuscript (preprint) (Other academic)
    Abstract [en]

    Background and purpose: To evaluate the long time outcome with regard to local tumour control, side effects and quality of life of a combined pulsed dose rate (PDR) boost and hyperfractionated accelerated external beam radiotherapy (EBRT) for primary base of tongue (BOT) cancers.

    Patients and methods: Between 1994 and 2007 we treated 83 patients, median age 60 (38-82) years, with primary T1-T4 BOT cancers. Seven patients (8 %) were T1-2N0 (AJCC stage I-II) and 76 (92 %) patients were T1-2N+ or T3-4N0-3 (AJCC stage III-IV). The mean estimated primary tumour volume was 15 (1-75) cm3.  EBRT was given with 1.7 Gy twice daily to 40,8 Gy to primary tumour and bilateral neck lymph nodes in 2.5 weeks. A PDR boost of 35 Gy and a neck dissection in clinical node positive cases was performed 2-3 weeks later. The patients were followed for a median of 54 (2-168) months.

    Results: The 2-, 5- and 10-years rates of actuarial local control were 91 %, 89 % and 85 %, overall survival 85 %, 65 % and 44 %, disease free survival 86 %, 80 % and 76 % respectively. The regional contral rate was 95 %. Six patients (7 %) developed distant metastases. Analysis of dosimetry showed a mean treated volume of 58 cm3.  In a review of late complications we found 11 (13 %) minor and 4 (5 %) major soft tissue necroses and 6 (7 %) osteoradionecroses. The patients median subjective SOMA/LENT scoring at last follow up was; grade 0 for pain and trismus, grade 1 for dysphagia and taste alteration and grade 2 for xerostomia. Global visual-analog-scale (VAS) scoring of quality of life was 8.

    Conclusions: Local and regional tumour control rate was excellent in this treatment protocol. The data support that PDR boost is at least as effective as published continuous low dose rate (CLDR) results.

  • 8.
    Karlsson, Leif
    et al.
    Örebro University, School of Health and Medical Sciences, Örebro University, Sweden. Department of Medical Physics, Örebro University Hospital, Örebro, Sweden.
    Thunberg, Per
    Örebro University, School of Health and Medical Sciences, Örebro University, Sweden. Örebro University Hospital. Department of Medical Physics, Örebro University Hospital, Örebro, Sweden.
    Johansson, Bengt
    Örebro University, School of Health and Medical Sciences, Örebro University, Sweden. Örebro University Hospital. Department of Oncology, Örebro University Hospital, Örebro, Sweden.
    Persliden, Jan
    Örebro University, School of Health and Medical Sciences, Örebro University, Sweden. Örebro University Hospital. Department of Medical Physics, Örebro University Hospital, Örebro, Sweden.
    The impact of activating source dwell positions outside the CTV on the dose to treated normal tissue volumes in TRUS guided 3D conformal interstitial HDR brachytherapy of prostate cancer2014In: Journal of Contemporary Brachytherapy, ISSN 1689-832X, E-ISSN 2081-2841, Vol. 6, no 3, p. 282-288Article in journal (Refereed)
    Abstract [en]

    Purpose: Dose coverage is crucial for successful treatment in mono-brachytherapy. Since few and very high dose fractions are used, there is an important balance between dwell positioning outside the clinical target volume (CTV) and possible damage on adjacent normal tissue. The purpose of this study was to evaluate the possibility of having dwell positions close to the CTV surface, while maintaining an acceptable dose distribution, and to investigate the robustness in terms of known geometrical uncertainties of the implant.

    Material and methods: This study included 37 patients who had received brachytherapy for prostate cancer as a monotherapy with the following schedules: 2 x 14 Gy or 3 x 11 Gy, each fraction separated by two weeks. The source dwell positions were activated 5 mm outside CTV. New optimizations were simulated for dwell positions at 3, 2, 1, and 0 mm. Inverse and graphical optimization were applied according to the relative dose constraints: V-100 CTV >= 97%, D-max,D- urethra <= 110%, and D-10 rectal mucosa <= 65%. The V-100 normal tissue outside CTV was used to evaluate dose variations caused by different dwell positions. Prostate geometries and dose distributions for the different dwell positions outside the CTV were used to investigate the impact on the CTV dose distribution due to geometrical uncertainties.

    Results: Both V-100,V- CTV, and V-100,V- normal tissue decreased, 98.6% to 92.2%, and 17 cm(3) to 9.0 cm(3), for dwell activation from 5 rum to 0 mm. The evaluation of both simulated longitudinal geometrical uncertainties and different source dwell activations implied that V-100,V- CTV ranged from 98.6% to 86.3%.

    Conclusions: It is possible to reduce the V-100,V- normal tissue by decreasing the source dwell positions outside the CTV from 5 to 3 mm, while maintaining dose constraints. In combination with the estimated geometrical uncertainties, however, the source dwell positions need to be 5 mm from the surface in order to maintain a robust implant.

  • 9.
    Kovács, György
    et al.
    Interdisciplinary Brachytherapy Unit, University of Lübeck, Lübeck, Germany; Uniklinik Lübeck (UKSH CL), Lübeck, Germany.
    Martinez-Monge, Rafael
    Department of Radiation Oncology, University of Navarra, Pamplona, Spain.
    Budrukkar, Ashwini
    Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India.
    Guinot, Jose Luis
    Department of Radiation Oncology, Fundacion Institito Valenciano de Oncologia (IVO), Valencia, Spain.
    Johansson, Bengt
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Oncology, Örebro University Hospital, Örebro, Sweden.
    Strnad, Vratislav
    Department of Radiation Oncology, University Hospital of Erlangen, Erlangen, Germany.
    Skowronek, Janusz
    Department of Brachytherapy, Greater Poland Cancer Centre, Poznan, Poland; Department of Elektroradiology, Poznan University of Medical Sciences, Poznań, Poland.
    Rovirosa, Angeles
    Department of Radiation Oncology, Hospital Clinic i Universitari, Barcelona, Spain.
    Siebert, Frank-André
    Department of Radiotherapy (Radiooncology), University Hospital Schleswig-Holstein (UKSH-C), Christian-Albrechts-University, Kiel, Germany.
    GEC-ESTRO ACROP recommendations for head & neck brachytherapy in squamous cell carcinomas: 1st update - Improvement by cross sectional imaging based treatment planning and stepping source technology2017In: Radiotherapy and Oncology, ISSN 0167-8140, E-ISSN 1879-0887, Vol. 122, no 2, p. 248-254Article in journal (Refereed)
    Abstract [en]

    The Head and Neck Working Group of the GEC-ESTRO (Groupe Européen de Curiethérapie - European Society for Therapeutic Radiology and Oncology) published in 2009 the consensus recommendations for low-dose rate, pulsed-dose rate and high-dose rate brachytherapy in head & neck cancers. The use of brachytherapy in combination with external beam radiotherapy and/or surgery was also covered as well as the use of brachytherapy in previously irradiated patients. Given the developments in the field, these recommendations needed to be updated to reflect up-to-date knowledge.

    The present update does not repeat basic knowledge which was published in the first recommendation but covers in a general part developments in (1) dose and fractionation, (2) aspects of treatment selection for brachytherapy alone versus combined BT+EBRT and (3) quality assurance issues.

    Detailed expert committee opinion intends to help the clinical practice in lip-, oral cavity-, oropharynx-, nasopharynx-, and superficial cancers. Different aspects of adjuvant treatment techniques and their results are discussed, as well the possibilities of salvage brachytherapy applications.

  • 10.
    Nyholm, Tufve
    et al.
    Department of Radiation Sciences, Umeå University, Umeå, Sweden; Medical Radiation Physics, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
    Olsson, Caroline
    Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden; Regional Cancer Center West, Western Sweden Healthcare Region, Göteborg, Sweden.
    Agrup, Måns
    Department of Oncology, Linköping University Hospital, Linköping, Sweden.
    Björk, Peter
    Department of Physics and Biomedical Engineering, Mälar Hospital, Eskilstuna, Sweden.
    Björk-Eriksson, Thomas
    Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.
    Gagliardi, Giovanna
    Department of Medical Physics, Karolinska University Hospital, Stockholm, Sweden.
    Grinåker, Hanne
    Swedish Radiation Safety Authority, Stockholm, Sweden.
    Gunnlaugsson, Adalsteinn
    Department of Oncology and Radiation Physics, Skåne University Hospital, Lund University, Lund, Sweden.
    Gustafsson, Anders
    Cureos AB, Uppsala, Sweden.
    Gustafsson, Magnus
    Department of Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden.
    Johansson, Bengt
    Örebro University, School of Medical Sciences. Department of Oncology, Örebro University Hospital, Örebro, Sweden.
    Johnsson, Stefan
    Department of Radiation Physics, Kalmar County Hospital, Kalmar, Sweden.
    Karlsson, Magnus
    Department of Radiation Sciences, Umeå University, Umeå, Sweden.
    Kristensen, Ingrid
    Department of Oncology and Radiation Physics, Skåne University Hospital, Lund University, Lund, Sweden.
    Nilsson, Per
    Department of Oncology and Radiation Physics, Skåne University Hospital, Lund University, Lund, Sweden.
    Nyström, Leif
    Department of Radiation Sciences, Umeå University, Umeå, Sweden.
    Onjukka, Eva
    Department of Medical Physics, Karolinska University Hospital, Stockholm, Sweden.
    Reizenstein, Johan
    Department of Oncology, Örebro University Hospital, Örebro University, Örebro, Sweden.
    Skönevik, Johan
    Department of Radiation Sciences, Umeå University, Umeå, Sweden.
    Soderström, Karin
    Department of Radiation Sciences, Umeå University, Umeå, Sweden.
    Valdman, Alexander
    Department of Oncology, Karolinska University Hospital, Stockholm, Sweden.
    Zackrisson, Bjorn
    Department of Radiation Sciences, Umeå University, Umeå, Sweden.
    Montelius, Anders
    Medical Radiation Physics, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
    A national approach for automated collection of standardized and population-based radiation therapy data in Sweden2016In: Radiotherapy and Oncology, ISSN 0167-8140, E-ISSN 1879-0887, Vol. 119, no 2, p. 344-350Article in journal (Refereed)
    Abstract [en]

    Purpose: To develop an infrastructure for structured and automated collection of interoperable radiation therapy (RT) data into a national clinical quality registry.

    Materials and methods: The present study was initiated in 2012 with the participation of seven of the 15 hospital departments delivering RT in Sweden. A national RT nomenclature and a database for structured unified storage of RT data at each site (Medical Information Quality Archive, MIQA) have been developed. Aggregated data from the MIQA databases are sent to a national RT registry located on the same IT platform (INCA) as the national clinical cancer registries.

    Results: The suggested naming convention has to date been integrated into the clinical workflow at 12 of 15 sites, and MIQA is installed at six of these. Involvement of the remaining 3/15 RT departments is ongoing, and they are expected to be part of the infrastructure by 2016. RT data collection from ARIA (R), Mosaiq (R), Eclipse (TM), and Oncentra (R) is supported. Manual curation of RT-structure information is needed for approximately 10% of target volumes, but rarely for normal tissue structures, demonstrating a good compliance to the RT nomenclature. Aggregated dose/volume descriptors are calculated based on the information in MIQA and sent to INCA using a dedicated service (MIQA2INCA). Correct linkage of data for each patient to the clinical cancer registries on the INCA platform is assured by the unique Swedish personal identity number.

    Conclusions: An infrastructure for structured and automated prospective collection of syntactically inter operable RT data into a national clinical quality registry for RT data is under implementation. Future developments include adapting MIQA to other treatment modalities (e.g. proton therapy and brachytherapy) and finding strategies to harmonize structure delineations. How the RT registry should comply with domain-specific ontologies such as the Radiation Oncology Ontology (ROO) is under discussion. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

  • 11.
    Tagliaferri, Luca
    et al.
    Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
    Budrukkar, Ashwini
    Tata Memorial Centre, Mumbai, India.
    Lenkowicz, Jacopo
    Fondazione Policlinico A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy.
    Cambeiro, Mauricio
    Clìnica Universidad de Navarra, Navarra, Spain.
    Bussu, Francesco
    Head of the Otolaryngology Division, Azienda Ospedaliero-Universitaria di Sassari, Italy.
    Guinot, Jose Luis
    Department of Radiation Oncology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain.
    Hildebrandt, Guido
    University Hospital Radiotherapy Department, University of Rostock, Rostock, Germany.
    Johansson, Bengt
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Oncology.
    Meyer, Jens E.
    Head & Neck Surgery Department, AK St. George Hospital, Hamburg, Germany.
    Niehoff, Peter
    Department of Radiotherapy, Sana Hospital Offenbach, Offenbach, Germany.
    Rovirosa, Angeles
    Hospital Clinic I Universitaria, Barcelona, Spain.
    Takacsi-Nagy, Zoltan
    National Cancer Institute, Budapest, Hungary.
    Boldrini, Luca
    Fondazione Policlinico A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy.
    Dinapoli, Nicola
    Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
    Lanzotti, Vito
    Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
    Damiani, Andrea
    Fondazione Policlinico A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy.
    Gatta, Roberto
    Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
    Fionda, Bruno
    Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
    Lancellotta, Valentina
    Radiation Oncology Section, Department of Surgical and Biomedical Science, University of Perugia and Perugia General Hospital, Perugia, Italy.
    Soror, Tamer
    Interdisciplinary Brachytherapy Unit, University of Lübeck – University Hospital S-H, Campus Lübeck, Germany.
    Monge, Rafael Martinez
    Clìnica Universidad de Navarra, Navarra, Spain.
    Valentini, Vincenzo
    Fondazione Policlinico A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy.
    Kovacs, Gyoergy
    Interdisciplinary Brachytherapy Unit, University of Lübeck – University Hospital S-H, Campus Lübeck, Germany.
    ENT COBRA ONTOLOGY: the covariates classification system proposed by the Head & Neck and Skin GEC-ESTRO Working Group for interdisciplinary standardized data collection in head and neck patient cohorts treated with interventional radiotherapy (brachytherapy)2018In: Journal of Contemporary Brachytherapy, ISSN 1689-832X, E-ISSN 2081-2841, Vol. 10, no 3, p. 260-266Article, review/survey (Refereed)
    Abstract [en]

    Purpose: Clinical data collecting is expensive in terms of time and human resources. Data can be collected in different ways; therefore, performing multicentric research based on previously stored data is often difficult. The primary objective of the ENT COBRA (COnsortium for BRachytherapy data Analysis) ontology is to define a specific terminological system to standardized data collection for head and neck (H&N) cancer patients treated with interventional radiotherapy.

    Material and methods: ENT-COBRA is a consortium for standardized data collection for H&N patients treated with interventional radiotherapy. It is linked to H&N and Skin GEC-ESTRO Working Group and includes 11 centers from 6 countries. Its ontology was firstly defined by a multicentric working group, then evaluated by the consortium followed by a multi-professional technical commission involving a mathematician, an engineer, a physician with experience in data storage, a programmer, and a software expert.

    Results: Two hundred and forty variables were defined on 13 input forms. There are 3 levels, each offering a specific type of analysis: 1. Registry level (epidemiology analysis); 2. Procedures level (standard oncology analysis); 3. Research level (radiomics analysis). The ontology was approved by the consortium and technical commission; an ad-hoc software architecture ("broker") remaps the data present in already existing storage systems of the various centers according to the shared terminology system. The first data sharing was successfully performed using COBRA software and the ENT COBRA Ontology, automatically collecting data directly from 3 different hospital databases (Lubeck, Navarra, and Rome) in November 2017.

    Conclusions: The COBRA Ontology is a good response to the multi-dimensional criticalities of data collection, retrieval, and usability. It allows to create a software for large multicentric databases with implementation of specific remapping functions wherever necessary. This approach is well-received by all involved parties, primarily because it does not change a single center's storing technologies, procedures, and habits.

  • 12.
    Tagliaferri, Luca
    et al.
    Department of Radiation Oncology – Gemelli-ART, Università Cattolica del Sacro Cuore, Milano, Italy.
    Kovacs, Gyoergy
    Interdisciplinary Brachytherapy Unit, Universitätsklinikum Schleswig-Holstein, University of Lübeck, Lübeck, Germany.
    Autorino, Rosa
    Department of Radiation Oncology – Gemelli-ART, Università Cattolica del Sacro Cuore, Milano, Italy.
    Budrukkar, Ashwini
    Tata Memorial Centre, Mumbai, India.
    Luis Guinot, Jose
    Department of Radiation Oncology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain.
    Hildebrand, Guido
    University Hospital Radiotherapy Department, University of Rostock, Rostock, Germany.
    Johansson, Bengt
    Örebro University, School of Medical Sciences. Department of Oncology, Örebro University Hospital, Örebro, Sweden.
    Martinez Monge, Rafael
    Clìnica Universidad de Navarra, Navarra, Spain.
    Meyer, Jens E.
    Head & Neck Surgery Department, AK St. George Hospital, Hamburg, Germany.
    Niehoff, Peter
    University Witten Herdecke, Cologne, Germany.
    Rovirosa, Angeles
    Hospital Clinic I Universitari, Barcelona, Spain.
    Takocsi-Nagy, Zoltan
    National Cancer Institute, Budapest, Hungary.
    Dinapoli, Nicola
    Department of Radiation Oncology – Gemelli-ART, Università Cattolica del Sacro Cuore, Milano, Italy.
    Lanzotti, Vito
    KBO-Labs – Gemelli-ART, Università Cattolica del Sacro Cuore, Milano, Italy.
    Damiani, Andrea
    KBO-Labs – Gemelli-ART, Università Cattolica del Sacro Cuore, Milano, Italy.
    Soror, Tamer
    Interdisciplinary Brachytherapy Unit, Universitätsklinikum Schleswig-Holstein, University of Lübeck, Lübeck, Germany.
    Valentini, Vincenzo
    Department of Radiation Oncology – Gemelli-ART, Università Cattolica del Sacro Cuore, Milano, Italy.
    ENT COBRA (Consortium for Brachytherapy Data Analysis): interdisciplinary standardized data collection system for head and neck patients treated with interventional radiotherapy (brachytherapy)2016In: Journal of Contemporary Brachytherapy, ISSN 1689-832X, E-ISSN 2081-2841, Vol. 8, no 4, p. 336-343Article, review/survey (Refereed)
    Abstract [en]

    Purpose: Aim of the COBRA (Consortium for Brachytherapy Data Analysis) project is to create a multicenter group (consortium) and a web-based system for standardized data collection.

    Material and methods: GEC-ESTRO (Groupe Europeen de Curietherapie - European Society for Radiotherapy & Oncology) Head and Neck (H&N) Working Group participated in the project and in the implementation of the consortium agreement, the ontology (data-set) and the necessary COBRA software services as well as the peer reviewing of the general anatomic site-specific COBRA protocol. The ontology was defined by a multicenter task-group.

    Results: Eleven centers from 6 countries signed an agreement and the consortium approved the ontology. We identified 3 tiers for the data set: Registry (epidemiology analysis), Procedures (prediction models and DSS), and Research (radiomics). The COBRA-Storage System (C-SS) is not time-consuming as, thanks to the use of "brokers", data can be extracted directly from the single center's storage systems through a connection with "structured query language database" (SQL-DB), Microsoft Access, FileMaker Pro, or Microsoft Excel. The system is also structured to perform automatic archiving directly from the treatment planning system or afterloading machine. The architecture is based on the concept of "on-purpose data projection". The C-SS architecture is privacy protecting because it will never make visible data that could identify an individual patient. This C-SS can also benefit from the so called "distributed learning" approaches, in which data never leave the collecting institution, while learning algorithms and proposed predictive models are commonly shared.

    Conclusions: Setting up a consortium is a feasible and practicable tool in the creation of an international and multi-system data sharing system. COBRA C-SS seems to be well accepted by all involved parties, primarily because it does not influence the center's own data storing technologies, procedures, and habits. Furthermore, the method preserves the privacy of all patients.

  • 13.
    Wickberg, Åsa
    et al.
    Örebro University, School of Medical Sciences.
    Liljegren, Göran
    Department of surgery, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Ahlgren, Johan
    Department of oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Karlsson, Leif
    Department of oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    With, Anders
    Department of oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Johansson, Bengt
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of oncology.
    Intraoperative high dose rate brachytherapy during breast-conserving surgery: a prospective pilot studyManuscript (preprint) (Other academic)
  • 14.
    Widmark, A.
    et al.
    Radiation Sciences/Onkology, Umeå University, Umeå, Sweden.
    Gunnlaugsson, A.
    Dept. of Oncology and Radiation Physics, Skåne University Hospital, Lund University, Lund, Sweden .
    Beckman, L.
    Dept. Radiation Sciences, Sundsvall Hospital, Sundsvall, Sweden; Umeå University, Umeå, Sweden.
    Thellenberg-Karlsson, C.
    Radiation Sciences/Oncology, Umeå University, Umeå, Sweden.
    Hoyer, M.
    Danish Centre For Particle Therapy, Aarhus University Hospital, Aarhus, Denmark .
    Lagerlund, M.
    Department Of Oncology, Kalmar Hospital, Kalmar, Sweden .
    Fransson, P.
    Umeå University, Radiation Sciences/Onkology, Umeå, Sweden.
    Tavelin, B.
    Radiation Sciences/Onkology, Umeå University, Umeå, Sweden.
    Norman, D. B.
    Regional Cancer Centre North, Umeå University Hospital, Umeå, Sweden .
    Kindblom, J.
    Department of Oncology, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
    Ginman, C.
    Department of Oncology, Karlstad Central Hospital, Karlstad, Sweden .
    Johansson, Bengt
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Oncology, Örebro University Hospital, Örebro, Sweden.
    Seke, M.
    Department of Oncology, Centrallasarettet Växjö, Växjö, Sweden.
    Björlinger, K.
    Department of Oncology, Jönköping Hospital, Jönköping, Sweden.
    Ågrup, M.
    Department of Oncology, Linköping University Hospital, Linköping, Sweden.
    Kjellen, E.
    Dept. of Oncology and Radiation Physics, Skåne University Hospital, Lund University, Lund, Sweden.
    Franzen, L.
    Radiation Sciences/Onkology, Umeå University, Umeå, Sweden.
    Nilsson, P.
    Dept. of Oncology and Radiation Physics, Skåne University Hospital, Lund University, Lund, Sweden .
    Ultrahypofractionation for prostate cancer: Outcome from the Scandinavian phase 3 HYPO-RT-PC trial2018In: Radiotherapy and Oncology, ISSN 0167-8140, E-ISSN 1879-0887, Vol. 127, no Suppl. 1, p. S314-S314Article in journal (Other academic)
  • 15.
    Widmark, Anders
    et al.
    Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.
    Gunnlaugsson, Adalsteinn
    Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund University, Lund, Sweden.
    Beckman, Lars
    Department of Oncology, Sundsvall Hospital, Sundsvall, Sweden.
    Thellenberg-Karlsson, Camilla
    Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.
    Hoyer, Morten
    Department of Oncology and Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.
    Lagerlund, Magnus
    Department of Oncology, Kalmar Hospital, Kalmar, Sweden.
    Kindblom, Jon
    Department of Oncology, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
    Ginman, Claes
    Department of Oncology, Karlstad Central Hospital, Karlstad, Sweden.
    Johansson, Bengt
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Oncology.
    Björnlinger, Kirsten
    Department of Oncology, Ryhov Hospital, Jönköping, Sweden.
    Seke, Mihajl
    Department of Oncology, Centrallasarettet, Växjö, Sweden.
    Agrup, Mans
    Department of Oncology, Linköping University Hospital, Linköping, Sweden.
    Fransson, Per
    Department of Nursing, Umeå University, Umeå, Sweden.
    Tavelin, Björn
    Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.
    Norman, David
    Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.
    Zackrisson, Björn
    Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.
    Anderson, Harald
    Department of Clinical Sciences Lund, Cancer Epidemiology, Lund University, Lund, Sweden.
    Kjellén, Elisabeth
    Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund University, Lund, Sweden.
    Franzén, Lars
    Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.
    Nilsson, Per
    Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund University, Lund, Sweden.
    Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial2019In: The Lancet, ISSN 0140-6736, E-ISSN 1474-547X, Vol. 394, no 10196, p. 385-395Article in journal (Refereed)
    Abstract [en]

    Background: Hypofractionated radiotherapy for prostate cancer has gained increased attention due to its proposed high radiation-fraction sensitivity. Recent reports from studies comparing moderately hypofractionated and conventionally fractionated radiotherapy support the clinical use of moderate hypofractionation. To date, there are no published randomised studies on ultra-hypofractionated radiotherapy. Here, we report the outcomes of the Scandinavian HYPO-RTPC phase 3 trial with the aim to show non-inferiority of ultra-hypofractionation compared with conventional fractionation.

    Methods: In this open-label, randomised, phase 3 non-inferiority trial done in 12 centres in Sweden and Denmark, we recruited men up to 75 years of age with intermediate-to-high-risk prostate cancer and a WHO performance status between 0 and 2. Patients were randomly assigned to ultra-hypofractionation (42.7 Gy in seven fractions, 3 days per week for 2.5 weeks) or conventional fractionated radiotherapy (78.0 Gy in 39 fractions, 5 days per week for 8 weeks). No androgen deprivation therapy was allowed. The primary endpoint was time to biochemical or clinical failure, analysed in the per-protocol population. The prespecified non-inferiority margin was 4% at 5 years, corresponding to a critical hazard ratio (HR) limit of 1.338. Physician-recorded toxicity was measured according to the Radiation Therapy Oncology Group (RTOG) morbidity scale and patient-reported outcome measurements with the Prostate Cancer Symptom Scale (PCSS) questionnaire. This trial is registered with the ISRCTN registry, number ISRCTN45905321.

    Findings: Between July 1, 2005, and Nov 4, 2015, 1200 patients were randomly assigned to conventional fractionation (n=602) or ultra-hypofractionation (n=598), of whom 1180 (591 conventional fractionation and 589 ultra-hypofractionation) constituted the per-protocol population. 1054 (89%) participants were intermediate risk and 126 (11%) were high risk. Median follow-up time was 5.0 years (IQR 3.1-7.0). The estimated failure-free survival at 5 years was 84% (95% CI 80-87) in both treatment groups, with an adjusted HR of 1.002 (95% CI 0.758-1.325; log-rank p=0.99). There was weak evidence of an increased frequency of acute physician-reported RTOG grade 2 or worse urinary toxicity in the ultra-hypofractionation group at end of radiotherapy (158 [28%] of 569 patients vs 132 [23%] of 578 patients; p=0.057). There were no significant differences in grade 2 or worse urinary or bowel late toxicity between the two treatment groups at any point after radiotherapy, except for an increase in urinary toxicity in the ultra-hypofractionation group compared to the conventional fractionation group at 1-year follow-up (32 [6%] of 528 patients vs 13 [2%] of 529 patients; (p=0.0037). We observed no differences between groups in frequencies at 5 years of RTOG grade 2 or worse urinary toxicity (11 [5%] of 243 patients for the ultra-hypofractionation group vs 12 [5%] of 249 for the conventional fractionation group; p=1.00) and bowel toxicity (three [1%] of 244 patients vs nine [4%] of 249 patients; p=0.14). Patient-reported outcomes revealed significantly higher levels of acute urinary and bowel symptoms in the ultra-hypofractionation group compared with the conventional fractionation group but no significant increases in late symptoms were found, except for increased urinary symptoms at 1-year follow-up, consistent with the physician-evaluated toxicity.

    Interpretation: Ultra-hypofractionated radiotherapy is non-inferior to conventionally fractionated radiotherapy for intermediate-to-high risk prostate cancer regarding failure-free survival. Early side-effects are more pronounced with ultra-hypofractionation compared with conventional fractionation whereas late toxicity is similar in both treatment groups. The results support the use of ultra-hypofractionation for radiotherapy of prostate cancer. Copyright (C) 2019 Elsevier Ltd. All rights reserved.

  • 16.
    Wikström, Johan
    et al.
    Department of Surgical Sciences, Section of Radiology, Uppsala University, Uppsala, Sweden.
    Isacsson, Ulf
    Department of Immunology, Genetics and Pathology, Section of Medical Radiation Sci-ence, Uppsala University, Uppsala, Sweden.
    Johansson, Bengt
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Oncology, Örebro University Hospital, Örebro, Sweden.
    Lennernäs, Bo
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Oncology, Örebro University Hospital, Örebro, Sweden.
    Magnetic Resonance Compatibility of a Transponder Aimed for Radiotherapy Positioning - A Phantom Study2017In: Anticancer Research, ISSN 0250-7005, E-ISSN 1791-7530, Vol. 37, no 9, p. 4993-4996Article in journal (Refereed)
    Abstract [en]

    Background/Aim: Electromagnetic Positioning Systems (EMP) is a new position-ing technique in four-dimensional radiotherapy. Patients with implanted transponders may be referred for magnetic resonance imaging (MRI) making it important to establish the MR safety.

    Materials and Methods: Oranges were prepared with transponders and imaged on a 3T MR scanner with different sequences. Computed tomography (CT) was performed as comparison. MR artifacts were assessed. An estimation of the maximum transponder de-flection force and heating was made.

    Results: The mean measured displacement of transponders was 0.1 mm (range=0.03-0.3 mm). Artifacts were observed adjacent to transponders using all sequences. The deflection force on the transponder in the gantry was less than 38 mN. No heating was observed.

    Conclusion: The absence of any substantial movement, the weak measured deflection force and absence of observed heating speaks for the safe use of MR imaging with transponder 3T. Local artefacts makes evaluation impossible adjacent to transponders.

1 - 16 of 16
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf